3i appoints US healthcare business expert as lead partner
This article was originally published in Clinica
The North American healthcare division of private equity firm 3i (London, UK) has appointed John Moore as its lead partner. His chief remit will be to support the expansion of 3i’s healthcare investment strategy across the US. Mr Moore’s experience of healthcare business in this region is described by 3i as “extensive”. He joins from Morgan Stanley, where he was most recently head of global healthcare banking. He is the president of the Irvington Institute for Immunological Research.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.